At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
Talazoparibdrug
Likely dose
Talazoparib 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)
In Brief
A Phase 2 clinical trial evaluating Talazoparib for Prostate Cancer. Completed, enrolled 128 participants across 120 sites in 14 countries.
Detailed Summary
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesAustralia, Austria, Belgium, Brazil, France, Germany, Hungary, Italy, Netherlands, Poland, South Korea, Spain, United Kingdom, United States
CollaboratorsMedivation, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJul 2017
Primary CompletionSep 2020
Study CompletionMar 2023
TodayJul 2026
First PostedMay 11, 2017
Enrollment StartJul 4, 2017
Primary CompletionSep 4, 2020
Study CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.1 years ago
Interventions
Talazoparibdrug
1 mg daily